Floatz logo

Dapagliflozin

Diabetes Mellitus

Erbil Polytechnic UniversitySmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
81/ 100

Competitive context

42 Active assets in the Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Metformin
Erbil Polytechnic University
Phase 4A
Pioglitazone
Milton S. Hershey Medical Center
Phase 4BBB
Alogliptin
Takeda
Phase 3BBB
Glibenclamide
Takeda
Phase 4BBB
Aspirin
Region Skane
Phase 4BBB

View all 49 →

Same molecule, other indications

Dapagliflozin is also rated in:

type 2 diabetes mellitusActive
BBB
Indicative · Phase 4
78 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseActive
BBB
Indicative · Phase 4
77 / 100
View asset →
arteriosclerosis disorderActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →